# GCC Agonist Signal in the Small Intestine

> **NCT05107219** · PHASE1 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 43 (actual)

## Conditions studied

- Barrett Esophagus
- Gastroesophageal Reflux Disease
- Malignant Digestive System Neoplasm

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Esophagogastroduodenoscopy
- **DRUG:** Linaclotide
- **DRUG:** Plecanatide

## Key facts

- **NCT ID:** NCT05107219
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-30
- **Primary completion:** 2026-02-06
- **Final completion:** 2026-02-06
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05107219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05107219, "GCC Agonist Signal in the Small Intestine". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05107219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*